Entrada Therapeutics (NASDAQ: TRDA) net income
Entrada Therapeutics reported a net loss of $143.8m for fiscal 2025; in fiscal 2024 it reported a net profit of $65.6m. Earnings per share were −$3.47.
Entrada Therapeutics's best year of the last 6 was fiscal 2024. It reported a loss in 5 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$143.8m | −319.0% | −565.5% | −$3.47 |
| 2024 | $65.6m | — | 31.1% | $1.76 |
| 2023 | −$6.7m | — | −5.2% | −$0.20 |
| 2022 | −$94.6m | — | — | −$3.02 |
| 2021 | −$51.2m | — | — | −$8.16 |
| 2020 | −$26.5m | — | — | −$24.00 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Entrada Therapeutics net income compared with its sector
By net income for its latest fiscal year, Entrada Therapeutics ranks 377th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Entrada Therapeutics, −565.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 375th | Alphatec | −$143.4m | −18.8% |
| 376th | Upstream Bio | −$143.4m | −5,026.0% |
| 377th | Entrada Therapeutics | −$143.8m | −565.5% |
| 378th | Charles River Laboratories | −$144.3m | −3.6% |
| 379th | Amylyx Pharmaceuticals | −$144.7m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Entrada Therapeutics
- How much did Entrada Therapeutics earn in fiscal 2025?
- Entrada Therapeutics reported a net loss of $143.8m for fiscal 2025. In fiscal 2024 it reported a net profit of $65.6m.
- What are the earnings per share of Entrada Therapeutics?
- They were −$3.47 in fiscal 2025, compared with $1.76 in fiscal 2024.
- What was the most profitable year for Entrada Therapeutics?
- Of its last 6 fiscal years, fiscal 2024, with $65.6m.
- Where does Entrada Therapeutics rank in its sector by net income?
- It ranks 377th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Entrada Therapeutics come from?
- From the annual report (Form 10-K) that Entrada Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Entrada Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Entrada Therapeutics: the Entrada Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.